Search clinical trials for: raltegravir and tenofovir and lamivudine

Total 269722 results

First Affiliated Hospital Xi'an Jiaotong University

Unknown

Study of Antiretroviral Therapy to Prevent HBV Intrauterine Infection

Hepatitis B, Chronic

China
Catholic University of the Sacred Heart

Completed

Raltegravir Switch for Toxicity or Adverse Events (RaSTA)

HIV Infections | HIV/AIDS | Antiretroviral Therapy

Italy
Yunnan AIDS Care Center

Unknown

Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients

HIV Infections | HBV Coinfection

China
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Ministry of Health, Brazil

Completed

Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis (REFLATE TB2)

Tuberculosis | HIV-1 Infection

France, Vietnam, Brazil, Côte D'Ivoire, Mozambique
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Terminated

RESIST-2: 2nd-line ART for HIV-2 Infection (RESIST-2)

HIV-2 Infection

Senegal
ANRS, Emerging Infectious Diseases

Completed

First-Line Treatment for HIV-2 (FIT-2)

HIV-2 Infection

Côte D'Ivoire, Burkina Faso, Senegal, Togo
Merck Sharp & Dohme LLC

Completed

Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)

HIV-1 | Central Nervous System
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide

HIV Infections

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study of Options for Second-Line Effective Combination Therapy (SELECT) (SELECT)

HIV-1 Infection

Peru, Kenya, Malawi, Brazil, South Africa, Zimbabwe, India, Thailand, Tanzania
ViiV Healthcare

Completed

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Canada, Belgium, Portugal, Italy, France, United Kingdom
ANRS, Emerging Infectious Diseases
MSD France

Not yet recruiting

DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection (ELDORADO)

HIV-1-infection

Brazil, Cambodia, Cameroon, Côte D'Ivoire, France, Mozambique
Rigshospitalet, Denmark
University of Copenhagen

Completed

Backup With Combivir or Single Dose (SD) Truvada in Order to Avoid Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance After SD Nevirapine for the Prevention of Mother-to-child Transmission (PMTCT)

HIV Infections

Tanzania
Professor Francois Venter

Recruiting

ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance (ADORE)

HIV-1-infection

South Africa
Professor Francois Venter

Completed

DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV (DORA)

HIV-1-infection

South Africa
Fenway Community Health
Merck Sharp & Dohme LLC

Completed

HIV Non Occupational Post-Exposure Prophylaxis (PEP)

HIV Infections

United States
Merck Sharp & Dohme LLC

Completed

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

HIV-1 Infection

United States, Chile, France, United Kingdom
Guy's and St Thomas' NHS Foundation Trust

Completed

Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection (R-PrEP)

Hiv

United Kingdom
Makerere University
Massachusetts General Hospital

Completed

Transgender Men and HIV in Uganda: PrEP Uptake and Persistence

PrEP | HIV | Sexually Transmitted Infections | Transgender Men

Uganda
Metropolis Medical
Merck Sharp & Dohme LLC

Completed

Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria (RALPIR)

HIV Infections | Proteinuria
Denver Infectious Disease Consultants, PLLC
GlaxoSmithKline

Unknown

Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects (SHIELD)

HIV Infections

United States
Gilead Sciences

Completed

SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection

HIV Infections

United Kingdom
Central Institute of Epidemiology, Moscow, Russia
Merck Sharp & Dohme LLC

Unknown

Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients

HIV Infections | Tuberculosis

Russian Federation
ViiV Healthcare

Completed

Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure

HIV Infection

United States
Uijeongbu St. Mary Hospital

Unknown

Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus Adefovir

Proportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48
GlaxoSmithKline

Completed

Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV (HEAT)

HIV Infection

United States, Puerto Rico
Merck Sharp & Dohme LLC

Completed

Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292) (onceMRK)

HIV Infection
Andrew Carr
Merck Sharp & Dohme LLC

Completed

Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men (RAL-NPEP)

HIV Infections | HIV Prevention

Australia
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Gilead Sciences

Completed

Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients (VIH-2)

HIV-2 Infection

France
University of California, San Francisco
Merck Sharp & Dohme LLC; Gilead Sciences; California HIV/AIDS Research Program

Completed

HIV Persistence and Viral Reservoirs

HIV Infections | HIV

United States
The University of Texas Health Science Center,...
Merck Sharp & Dohme LLC; Gilead Sciences

Completed

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

HIV

United States
Taipei Veterans General Hospital, Taiwan
China Medical University Hospital; Kaohsiung Medical University Chung-Ho Memorial... and other collaborators

Unknown

Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients

Chronic Hepatitis B

Taiwan
National Institute of Allergy and Infectious Diseases...
Adult AIDS Clinical Trials Group

Completed

Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

HIV Infections

United States
University of Alabama at Birmingham
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Recruiting

Reducing Vertical Transmission of Hepatitis B in Africa (REVERT-B)

Hepatitis B Infection

United States
Myanmar Oxford Clinical Research Unit
Institute of Tropical Medicine, Belgium; Medical Action Myanmar

Completed

PrEP Among MSM and TG in Myanmar (PrEP)

HIV Infections

Myanmar
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030) (DRIVE BEYOND)

HIV-1 Infection
St. Luke's-Roosevelt Hospital Center
Gilead Sciences

Completed

Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects (TRU)

HIV

United States
Radboud University Medical Center

Completed

Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients (PRADA)

HIV Infections | HIV Infection

Germany, Netherlands
Johnson & Johnson Pte Ltd

Terminated

A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (RISE)

Human Immunodeficiency Virus Infections

India
Kirby Institute
Merck Sharp & Dohme LLC

Completed

The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection (PINT)

HIV Infection

Australia
Bristol-Myers Squibb

Terminated

A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection

Chronic Hepatitis B

Germany, Turkey, United States, Poland, Belgium, Italy
David A Wohl, MD
Merck Sharp & Dohme LLC

Completed

Raltegravir as Early Therapy in African-Americans Living With HIV Study (REAL)

HIV Infections

United States
St Stephens Aids Trust

Completed

Atripla to Raltegravir Switch Study for CNS Toxicity (SSAT036)

HIV Infection

United Kingdom
Johns Hopkins University
National Institute on Drug Abuse (NIDA)

Completed

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

HIV Infection | Hepatitis C

United States
Charlotte-Paige Rolle, MD
ViiV Healthcare

Completed

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF (DYAD)

HIV I Infection

United States
David Garcia Cinca
Fundacion Clinic per a la Recerca Biomédica

Unknown

Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM (RALAM-RollOver)

HIV Infections | HIV Seropositivity | HIV-1-infection

Spain
David Garcia Cinca
Fundacion Clinic per a la Recerca Biomédica

Unknown

Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen (RALAM-II)

HIV Infections | HIV Seropositivity | HIV-1-infection

Spain
University of Zurich

Recruiting

Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study

HIV Infections

Switzerland
Giovanni Di Perri
University of Turin, Italy; University of Milan

Terminated

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir (RALBAT)

HIV Infection | Osteopenia

Italy
University of Colorado, Denver

Completed

Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites

HIV-1-infection

United States
Merck Sharp & Dohme LLC

Completed

Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021) (DRIVE-AHEAD)

Human Immunodeficiency Virus (HIV)

3

Subscribe